Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Powell

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Science Translational Medicine|April 13, 2018
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancerJanos L Tanyi, Sara Bobisse, Eran Ophir, et al.
Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
Neuronal cell adhesion molecule (NRCAM) variant defined by microexon skipping is an essential, antigenically distinct, and targetable proteoform in high-grade gliomaPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Cancer Cell|November 5, 2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulationJaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, et al.
Nature Reviews. Cancer|October 24, 2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D Bowtell, Steffen Böhm, Ahmed A Ahmed, et al.
Cancer Cell|August 1, 2025
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancerEleonora Ghisoni, Fabrizio Benedetti, Aspram Minasyan, et al.
Cancer|March 6, 2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceRobert C Bast, Ursula A Matulonis, Anil K Sood, et al.
Science Immunology|July 19, 2024
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P Patel, Guido Ghilardi, Yunlin Zhang, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Science Translational Medicine|April 13, 2018
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancerJanos L Tanyi, Sara Bobisse, Eran Ophir, et al.
Cell Reports|August 9, 2025
NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomasPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
Neuronal cell adhesion molecule (NRCAM) variant defined by microexon skipping is an essential, antigenically distinct, and targetable proteoform in high-grade gliomaPriyanka Sehgal, Ammar S Naqvi, Makenna Higgins, et al.
Cancer Cell|November 5, 2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulationJaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, et al.
Nature Reviews. Cancer|October 24, 2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D Bowtell, Steffen Böhm, Ahmed A Ahmed, et al.
Cancer Cell|August 1, 2025
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancerEleonora Ghisoni, Fabrizio Benedetti, Aspram Minasyan, et al.
Cancer|March 6, 2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceRobert C Bast, Ursula A Matulonis, Anil K Sood, et al.
Science Immunology|July 19, 2024
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P Patel, Guido Ghilardi, Yunlin Zhang, et al.
Pageof 14